(firstQuint)Safety and Immunogenicity of Fluzone Quadrivalent and Fluzone High-Dose, Influenza Vaccines.

 This study will assess the safety and immunogenicity profiles of Fluzone Quadrivalent vaccine in children and adults and Fluzone High-Dose vaccine in older adults.

 Immunogenicity outcomes (GMTs, GMT ratios, seroprotection, and seroconversion) will be assessed, as appropriate, on Day 0 (pre-vaccination) and Day 28 post-final vaccination for subjects 6 months to 18 years of age.

 Solicited reactions, unsolicited non-serious adverse events, and serious adverse events will also be reported.

.

 Safety and Immunogenicity of Fluzone Quadrivalent and Fluzone High-Dose, Influenza Vaccines@highlight

This multicenter, open-label, Phase IV study was designed to describe the safety and immunogenicity of Fluzone Quadrivalent vaccine in children 6 months to 65 years of age.

